Back to Search
Start Over
Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study.
- Source :
-
Clinical Immunology . Aug2022, Vol. 241, pN.PAG-N.PAG. 1p. - Publication Year :
- 2022
-
Abstract
- Myasthenic crisis (MC) is a life-threatening state with respiratory failure in patients with myasthenia gravis (MG). The fast-acting immunomodulatory therapies for treating MC included plasma exchange (PE) and intravenous immunoglobulin (IVIG). However, the efficacy and the impact on antibody changes remained unknown. We prospectively followed 40 anti-acetylcholine receptors (AChR) antibody-positive MC patients who received either PE (n = 12) or IVIG (n = 28) at crisis. PE was associated with a reduced ICU stay length (p = 0.018) and an early response by the average changes in MGFA-QMG (p = 0.003), MMT (p = 0.020), and ADL (p = 0.011) at one-week off-ventilation. However, the clinical efficacy was equally comparable in both groups after 1 month. Post-treatment hemoglobin drop was significant in both groups, while IVIG was associated with a significant reduction in anti-AChR antibody titers (p < 0.001). This analysis provides real-world evidence in supporting the use of PE as a fast-acting therapy for shortening the ICU stay in AChR-associated MC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15216616
- Volume :
- 241
- Database :
- Academic Search Index
- Journal :
- Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 158369551
- Full Text :
- https://doi.org/10.1016/j.clim.2022.109058